Abiopharma

Coursera to Announce First Quarter 2026 Financial Results

Non-Binding Term Sheet for $17.5 Million Strategic Investment at Significant Premium to Current Market Price and Focus on Defense Collaboration

Foresight Enters Non-Binding Term Sheet for $17.5 Million Strategic Investment at Significant Premium to Current Market Price and Focus on Defense Collaboration

YY Group Reports Unaudited Second Half and Full Year 2025 Earnings Results Highlighting Accelerating Revenue Growth, Expanding Margins and Positioning for Profitability in 2026

Vertical Aerospace Announces Execution and Closing of Comprehensive Financing Package of up to $850 Million

dLocal Limited Announces Dismissal of New York State Securities Class Action

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Net Asset Value(s)

Calidi Biotherapeutics - Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research